Exelixis (EXEL) opened 2026 with Q1 revenue of US$610.8 million and basic EPS of US$0.81, setting a clear marker for how the year is starting to shape up. The company has seen quarterly revenue move from US$555.4 million in Q1 2025 to US$610.8 million in Q1 2026, while basic EPS over that same span shifted from US$0.57 to US$0.81. This is prompting investors to focus on how sustained profitability and margins might influence sentiment around the latest numbers.

See our full analysis for Exelixis.

The next step is to compare these fresh results with the widely held narratives around Exelixis to see which views the numbers support and which might need to be reconsidered.

Net income and margins stand out in Q1 2026

• Q1 2026 net income (excluding extra items) came in at US$210.5 million, compared with US$159.6 million in Q1 2025. Trailing 12 month net income is US$833.4 million on US$2.4b of revenue, implying a 35.1% net margin versus 28% in the prior trailing period.
• What supports the bullish view is that this 35.1% trailing margin sits alongside five year earnings growth of 37.6% per year. Bulls point to this combination as evidence of an oncology business that is turning revenue into profit at scale, even as they acknowledge pipeline and pricing risks.

Valuation metrics vs growth expectations

• On the trailing numbers, Exelixis trades on a P/E of 14.8x compared with a peer average of 25x and a US biotech industry average of 17.8x. The current share price of US$48.70 is well below the DCF fair value of US$256.76.
• Consensus narrative suggests revenue is forecast to grow 7.3% per year and earnings 14.3% per year. This is more moderate than the 37.6% five year earnings growth, so investors weighing that slower forecast against the lower than peer P/E and the DCF fair value are essentially deciding whether the current valuation already reflects a cooler growth phase or still leaves room if margins at around 35.1% are sustained.

To see how bulls connect these margin and valuation numbers to their long term thesis for Exelixis, check out the 🐂 Exelixis Bull Case.

Testing margin pressure worries against recent results

• Bears highlight rising discount pressure and heavy reliance on cabozantinib, and set that against a trailing net profit margin of 35.1% versus 28% a year earlier and trailing 12 month revenue of US$2.4b, where Q1 2026 alone contributed US$610.8 million of revenue and US$210.5 million of net income (excluding extra items).
• Bears argue that regulatory and payer discounts could pull margins down from here, yet the recent data show margins at 35.1% and five year earnings growth of 37.6% per year. The cautious view therefore leans heavily on future risks such as pricing pressure, increasing 340B mix and pipeline execution rather than any current collapse in profitability, which is why some investors also pay close attention to the minor red flag of recent insider selling.

Skeptics focus on pricing pressure and pipeline risk, so if you want to see how that case is built from the ground up, take a look at the 🐻 Exelixis Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Exelixis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards on the table, sentiment around Exelixis is clearly mixed. Move quickly, review the numbers, and weigh the 4 key rewards and 1 important warning sign.

See What Else Is Out There

Exelixis leans heavily on cabozantinib and faces pricing and regulatory pressure worries, so future earnings and margins may not match past trends.

If that reliance and uncertainty leaves you uneasy, compare it with companies screened for stronger resilience and stability using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.